metaLead Therapeutics AG

At metaLead, we are pioneering the next generation of Radioligand Therapy (RLT) through the development of our proprietary pipeline of targeted radiopharmaceuticals. Our core innovation lies in the design of advanced chelators that securely bind potent therapeutic radioisotopes. By engineering these critical structures to achieve unprecedented in vivo stability and optimized biodistribution, we ensure that radioisotopes remain firmly anchored until they reach the tumor microenvironment. This drastically minimizes systemic toxicity while maximizing anti-tumor efficacy. We are actively advancing our internal therapeutic programs toward in vivo proof of concept, with a focus on translating our structural innovations into highly effective precision oncology treatments for patients.